NO20070876L - Apolipoprotein A1 mimetics og anvendelser derav. - Google Patents

Apolipoprotein A1 mimetics og anvendelser derav.

Info

Publication number
NO20070876L
NO20070876L NO20070876A NO20070876A NO20070876L NO 20070876 L NO20070876 L NO 20070876L NO 20070876 A NO20070876 A NO 20070876A NO 20070876 A NO20070876 A NO 20070876A NO 20070876 L NO20070876 L NO 20070876L
Authority
NO
Norway
Prior art keywords
apolipoprotein
mimetics
cholesterol levels
plasma cholesterol
useful
Prior art date
Application number
NO20070876A
Other languages
English (en)
Norwegian (no)
Inventor
William W Bachovchin
Original Assignee
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College filed Critical Tufts College
Publication of NO20070876L publication Critical patent/NO20070876L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20070876A 2004-07-16 2007-02-15 Apolipoprotein A1 mimetics og anvendelser derav. NO20070876L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58872204P 2004-07-16 2004-07-16
PCT/US2005/025182 WO2006020040A2 (en) 2004-07-16 2005-07-15 Apolipoprotein a1 mimetics and uses thereof

Publications (1)

Publication Number Publication Date
NO20070876L true NO20070876L (no) 2007-03-30

Family

ID=35907926

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070876A NO20070876L (no) 2004-07-16 2007-02-15 Apolipoprotein A1 mimetics og anvendelser derav.

Country Status (12)

Country Link
US (3) US7569546B2 (cg-RX-API-DMAC10.html)
EP (1) EP1771473B1 (cg-RX-API-DMAC10.html)
JP (1) JP5048486B2 (cg-RX-API-DMAC10.html)
KR (1) KR101185609B1 (cg-RX-API-DMAC10.html)
CN (1) CN101076541A (cg-RX-API-DMAC10.html)
AU (1) AU2005275009B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0513402A (cg-RX-API-DMAC10.html)
CA (1) CA2574007A1 (cg-RX-API-DMAC10.html)
IL (1) IL180733A (cg-RX-API-DMAC10.html)
NO (1) NO20070876L (cg-RX-API-DMAC10.html)
TW (1) TWI377066B (cg-RX-API-DMAC10.html)
WO (1) WO2006020040A2 (cg-RX-API-DMAC10.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
JP5048486B2 (ja) * 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
KR20070089996A (ko) * 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
AU2006242651B2 (en) * 2005-04-29 2013-05-16 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
ES2402823T3 (es) * 2006-06-01 2013-05-09 Institut De Cardiologie De Montreal Compuesto para uso en el tratamiento de estenosis valvular
EP2049137A4 (en) * 2006-08-08 2013-05-01 Univ California SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
ATE533783T1 (de) 2006-12-13 2011-12-15 Univ California Potente und selektive mittlersubstanzen von cholesterolefflux
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
WO2009036460A2 (en) * 2007-09-14 2009-03-19 Ambrx, Inc. Modified human apolipoprotein a-i polypeptides and their uses
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) * 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US20110020242A1 (en) * 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
MX2011008599A (es) * 2009-02-16 2011-11-18 Cerenis Therapeutics Sa Peptidos mimeticos de la apolipoproteina a-i.
AU2014268255B2 (en) * 2009-02-16 2016-04-21 Cerenis Therapeutics Holding Sa Apolipoprotein a-i mimics
US20130310304A1 (en) * 2010-06-15 2013-11-21 Matthew C. Lawyer Compositions and methods for the treatment of atherosclerosis
LT2673296T (lt) * 2011-02-07 2019-02-25 Cerenis Therapeutics Holding Sa Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN103910802B (zh) * 2014-04-24 2017-01-11 华中科技大学 一种促进树突细胞摄取抗原肽的多肽、促进树突细胞摄取抗原肽的纳米颗粒及其应用
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポe模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
FR3026409B1 (fr) * 2014-09-26 2018-03-30 Centre National De La Recherche Scientifique (Cnrs) Procede de criblage de molecules interferentes
AU2016238290B9 (en) 2015-03-25 2019-06-13 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHOD FOR DELIVERING BIOMACROMOLECOLIC ACTIVE SUBSTANCES
AU2018210404B2 (en) * 2017-01-19 2022-01-27 Novo Nordisk A/S ApoC-II mimetic peptides
KR20260012291A (ko) 2018-07-12 2026-01-26 더 리젠츠 오브 더 유니버시티 오브 미시간 면역 반응을 조절할 수 있는 금속 함유 제형의 조성물 및 방법
KR20230004605A (ko) 2020-04-16 2023-01-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 급성 상태를 치료하는 방법
CA3197168A1 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3216226A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
US20250230208A1 (en) 2022-04-06 2025-07-17 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CA3258787A1 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa METHODS OF TREATMENT OF HYPERINFLAMMATORY DISEASES USING LIPID-BINDING PROTEIN COMPLEXES
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
KR20260010675A (ko) 2023-01-13 2026-01-21 아비오닉스 파마 에스에이 지질 결합 단백질 분자 치료
IL327995A (en) 2023-10-31 2026-06-01 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7105635B2 (en) * 2002-06-04 2006-09-12 The University Of Toledo Cyclic beta-sheet peptides useful as apoptotic/cytotoxic cancer agents
JP5048486B2 (ja) * 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
KR20070089996A (ko) * 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법

Also Published As

Publication number Publication date
US20120259091A1 (en) 2012-10-11
TWI377066B (en) 2012-11-21
TW200612977A (en) 2006-05-01
IL180733A (en) 2013-01-31
JP5048486B2 (ja) 2012-10-17
US8124580B2 (en) 2012-02-28
WO2006020040A2 (en) 2006-02-23
JP2008506709A (ja) 2008-03-06
BRPI0513402A (pt) 2008-05-06
CN101076541A (zh) 2007-11-21
EP1771473B1 (en) 2012-12-26
KR101185609B1 (ko) 2012-09-24
US7569546B2 (en) 2009-08-04
US20060069030A1 (en) 2006-03-30
AU2005275009B2 (en) 2011-12-08
EP1771473A2 (en) 2007-04-11
IL180733A0 (en) 2007-06-03
AU2005275009A1 (en) 2006-02-23
WO2006020040A3 (en) 2006-07-06
CA2574007A1 (en) 2006-02-23
KR20070095862A (ko) 2007-10-01
US20100009919A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
TW200612977A (en) Apolipoprotein A1 mimetics and uses thereof
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
WO2006045096A3 (en) Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
WO2007092622A3 (en) Compositions and methods for treating bone
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
NO20091700L (no) Florizinanaloger som inhibitorer av glukose-ko-transporter 2
DK1984357T3 (da) 2,4-pyrimidindiaminforbindelser til behandling eller forebyggelse af autoimmunsygdomme
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
NO20071050L (no) Rapamycin-polymorf II og anvendelser derav
DK2089369T3 (da) 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
PL2207786T3 (pl) 2'-fluoro-2'-deoksy tetrahydrouryny jako inhibitory dezaminazy cytydyny
NO20073105L (no) Pyridazinonforbindelser
EP2021797A4 (en) N-2,2,4-bis (1,1-dimethylethyl) -5-hydroxy-phenyl-1,4-dihydro-4-oxoquinol-3-carboxamide
TW200736253A (en) Pyridopyrazine derivatives and their use
TNSN08153A1 (en) Anti-hypercholesterolemic compounds
NO20082497L (no) Diarylureaer for behandling av pulmonal hypertensjon
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
ATE528989T1 (de) Kristalline feste rasagilin-base
MX2009007911A (es) Inhibidores de proteina tirosina fosfatasa 1b aromaticos fusionados.
NO20091353L (no) Serine hydrolaseinhibitorer
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
NO20071510L (no) 4-Amino-substituerte-2-substituerte-1,2,3,4-tetrahydrokinolinforbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application